Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine for Cognitive and Behavioral Impairment in Adults With ASD
NCT01333865Phase 4Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jan 2010
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of memantine in Autism Spectrum Disorder (ASD), sponsored by Massachusetts General Hospital. Primary endpoint: Social Responsiveness Scale at 12 weeks. Started Jan 2010; status: completed.
02
Drugs
memantine
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT01333865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01333865.